Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 3/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980904 | 0.69 | — | — | |
| SCHEMBL17530314 | 0.65 | — | — | |
| SCHEMBL5259013 | 0.65 | — | — | |
| SCHEMBL981305 | 0.65 | — | — | |
| Methyl Alcohol SCHEMBL27778739 | 0.65 | KDM4E (0.50) | CA1CA9TP53KDM4EMAPK1 | |
| SCHEMBL28110872 | 0.64 | CA1 (0.41) | CA1CA9TP53KDM4EMAPK1 | |
| SCHEMBL2213273 | 0.64 | — | — | |
| SCHEMBL31064854 | 0.64 | — | — | |
| SCHEMBL27642043 | 0.64 | KMT2A (0.51) | CA1CA9TP53KDM4EMAPK1 | |
| SCHEMBL12379211 | 0.64 | MAPT (0.45) | CA1CA9TP53KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202400-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| US-9714255-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-25 | — | — | US | disclosed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | disclosed |
| US-9127019-B2 | Cortistatin analogues and synthesis thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-23 | — | — | US | disclosed |
| US-20110207154-A1 | METHOD FOR DETERMINATION OF MARINOBUFAGENIN LEVELS AND COMPOUNDS EMPLOYABLE IN SUCH METHOD | SCOTT & WHITE HEALTHCARE (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110190323-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2334686-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | President and Fellows of Harvard College (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010024930-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | TEK, CTTN, FLT1 | CA1 2055/4885CA9 1648/4885TP53 927/4885 |
| US-20110190323-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, PROKR1 | CA1 2042/4885CA9 1777/4885TP53 1418/4885 |
| US-10202400-B2 | Cortistatin analogues and syntheses thereof | CTTN, TEK, FLT1 | CA1 2223/4885CA9 1723/4885TP53 1624/4885 |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | CA1 2223/4885CA9 1723/4885TP53 1624/4885 |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | CTTN, TEK, FLT1 | CA1 2223/4885CA9 1723/4885TP53 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.